1. Home
  2. EDRY vs SCLX Comparison

EDRY vs SCLX Comparison

Compare EDRY & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EuroDry Ltd.

EDRY

EuroDry Ltd.

HOLD

Current Price

$22.06

Market Cap

55.6M

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$9.99

Market Cap

52.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDRY
SCLX
Founded
2018
2011
Country
Greece
United States
Employees
N/A
34
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.6M
52.5M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
EDRY
SCLX
Price
$22.06
$9.99
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
29.1K
119.0K
Earning Date
06-04-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$28.30
$122.52
Revenue Next Year
$10.13
$186.30
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.78
$4.20
52 Week High
$28.00
$34.27

Technical Indicators

Market Signals
Indicator
EDRY
SCLX
Relative Strength Index (RSI) 47.05 63.02
Support Level $18.50 $7.73
Resistance Level $23.53 $12.32
Average True Range (ATR) 1.75 0.94
MACD -0.14 0.24
Stochastic Oscillator 36.51 78.36

Price Performance

Historical Comparison
EDRY
SCLX

About EDRY EuroDry Ltd.

EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: